Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct;30(4):914-928.
doi: 10.3350/cmh.2024.0296. Epub 2024 Aug 6.

Development and validation of a stromal-immune signature to predict prognosis in intrahepatic cholangiocarcinoma

Affiliations

Development and validation of a stromal-immune signature to predict prognosis in intrahepatic cholangiocarcinoma

Yu-Hang Ye et al. Clin Mol Hepatol. 2024 Oct.

Abstract

Backgrounds/aims: Intrahepatic cholangiocarcinoma (ICC) is a highly desmoplastic tumor with poor prognosis even after curative resection. We investigated the associations between the composition of the ICC stroma and immune cell infiltration and aimed to develop a stromal-immune signature to predict prognosis in surgically treated ICC.

Methods: We recruited 359 ICC patients and performed immunohistochemistry to detect α-smooth muscle actin (α-SMA), CD3, CD4, CD8, Foxp3, CD68, and CD66b. Aniline was used to stain collagen deposition. Survival analyses were performed to detect prognostic values of these markers. Recursive partitioning for a discrete-time survival tree was applied to define a stromal-immune signature with distinct prognostic value. We delineated an integrated stromal-immune signature based on immune cell subpopulations and stromal composition to distinguish subgroups with different recurrence-free survival (RFS) and overall survival (OS) time.

Results: We defined four major patterns of ICC stroma composition according to the distributions of α-SMA and collagen: dormant (α-SMAlow/collagenhigh), fibrogenic (α-SMAhigh/collagenhigh), inert (α-SMAlow/collagenlow), and fibrolytic (α-SMAhigh/collagenlow). The stroma types were characterized by distinct patterns of infiltration by immune cells. We divided patients into six classes. Class I, characterized by high CD8 expression and dormant stroma, displayed the longest RFS and OS, whereas Class VI, characterized by low CD8 expression and high CD66b expression, displayed the shortest RFS and OS. The integrated stromal-immune signature was consolidated in a validation cohort.

Conclusion: We developed and validated a stromal-immune signature to predict prognosis in surgically treated ICC. These findings provide new insights into the stromal-immune response to ICC.

Keywords: Immune cell; Intrahepatic cholangiocarcinoma; Prognosis; Stromal signature.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest

The authors have no conflicts to disclose.

Figures

Figure 1.
Figure 1.
Tumor stromal composition is associated with prognosis in ICC. (A) Stromal composition of different stromal types. (B) K-M curves of RFS and OS among stromal composition and different stromal types. ICC, intrahepatic cholangiocarcinoma; RFS, recurrencefree survival; OS, overall survival; α-SMA, α-smooth muscle actin.
Figure 2.
Figure 2.
Interactive of tumor infiltrated leukocytes regarding different stromal types. (A) Distribution of different tumor infiltrated leukocytes in different stromal types. (B) Comparative correlation analysis of tumor infiltrated leukocytes in different stroma types.
Figure 3.
Figure 3.
Integrating prognostic stromal-immune signature to predict recurrence-free survival. (A) Recursive partition survival tree defines the stromal-immune signature with separate median RFS and OS. (B) Pairwise survival analysis of stromal-immune signature with Bonferroni adjustment in left low triangle and none adjustment in right upper triangle for RFS and OS. (C) Boxplot illustrates the prognostic index by Cox multivariate model in different stromal-immune signature. RFS, recurrence-free survival; OS, overall survival.
None

References

    1. Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, et al. Expert consensus document: cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA) Nat Rev Gastroenterol Hepatol. 2016;13:261–280. - PubMed
    1. Mavros MN, Economopoulos KP, Alexiou VG, Pawlik TM. Treatment and prognosis for patients with intrahepatic cholangiocarcinoma: systematic review and meta-analysis. JAMA Surg. 2014;149:565–574. - PubMed
    1. Sirica AE, Gores GJ, Groopman JD, Selaru FM, Strazzabosco M, Wei Wang X, et al. Intrahepatic cholangiocarcinoma: continuing challenges and translational advances. Hepatology. 2019;69:1803–1815. - PMC - PubMed
    1. Tian MX, Zhou YF, Qu WF, Liu WR, Jin L, Jiang XF, et al. Histopathology-based immunoscore predicts recurrence for intrahepatic cholangiocarcinoma after hepatectomy. Cancer Immunol Immunother. 2019;68:1369–1378. - PMC - PubMed
    1. Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng W, Kim D, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med. 2015;21:938–945. - PMC - PubMed

MeSH terms

LinkOut - more resources